Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
Krzysztof M. Zak, P. Grudnik, Katarzyna Guzik, et al.
Oncotarget (2016) Vol. 7, Iss. 21, pp. 30323-30335
Open Access | Times Cited: 355

Showing 1-25 of 355 citing articles:

Revisiting the PD-1 pathway
Nikolaos Patsoukis, Qi Wang, Laura Strauss, et al.
Science Advances (2020) Vol. 6, Iss. 38
Open Access | Times Cited: 400
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
Krzysztof M. Zak, P. Grudnik, Katarzyna Magiera‐Mularz, et al.
Structure (2017) Vol. 25, Iss. 8, pp. 1163-1174
Open Access | Times Cited: 332
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Jinhua Liu, Zichao Chen, Yaqun Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 309
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Qian Wu, Jiang Li, Sicheng Li, et al.
Acta Pharmacologica Sinica (2020) Vol. 42, Iss. 1, pp. 1-9
Open Access | Times Cited: 300
Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1
Katarzyna Guzik, Krzysztof M. Zak, P. Grudnik, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 13, pp. 5857-5867
Open Access | Times Cited: 298
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Ju‐Yeun Lee, Hyun Tae Lee, Woo‐Ri Shin, et al.
Nature Communications (2016) Vol. 7, Iss. 1
Open Access | Times Cited: 261
Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
Łukasz Skalniak, Krzysztof M. Zak, Katarzyna Guzik, et al.
Oncotarget (2017) Vol. 8, Iss. 42, pp. 72167-72181
Open Access | Times Cited: 248
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Shuguang Tan, Hao Zhang, Yan Chai, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 231
Immunomodulators targeting the PD‐1/PD‐L1 protein‐protein interaction: From antibodies to small molecules
Jeffrey Yang, Longqin Hu
Medicinal Research Reviews (2018) Vol. 39, Iss. 1, pp. 265-301
Open Access | Times Cited: 164
Immune Checkpoint Blockade Mediated by a Small‐Molecule Nanoinhibitor Targeting the PD‐1/PD‐L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer
Rui Zhang, Zhiyan Zhu, Hongying Lv, et al.
Small (2019) Vol. 15, Iss. 49
Closed Access | Times Cited: 159
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
Pottayil G. Sasikumar, Naremaddepalli S. Sudarshan, Srinivas Adurthi, et al.
Communications Biology (2021) Vol. 4, Iss. 1
Open Access | Times Cited: 113
Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation
Tianyu Wang, Shi Cai, Yao Cheng, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 5, pp. 3879-3893
Closed Access | Times Cited: 88
Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy
Shuangneng Yin, Zhaojun Chen, Dugang Chen, et al.
Theranostics (2023) Vol. 13, Iss. 5, pp. 1520-1544
Open Access | Times Cited: 62
Molecular Glue Discovery: Current and Future Approaches
Jeffrey A. Dewey, Clémence Delalande, Saara‐Anne Azizi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 14, pp. 9278-9296
Open Access | Times Cited: 48
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
Sadique A. Javed, Asim Najmi, Waquar Ahsan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 29
Molecular glues for protein-protein interactions: Progressing toward a new dream
Markella Konstantinidou, Michelle R. Arkin
Cell chemical biology (2024) Vol. 31, Iss. 6, pp. 1064-1088
Open Access | Times Cited: 25
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Fei Zhang, Hudie Wei, Xiaoxiao Wang, et al.
Cell Discovery (2017) Vol. 3, Iss. 1
Open Access | Times Cited: 165
Stabilization of protein-protein interactions in drug discovery
Sebastian A. Andrei, Eline Sijbesma, Michael M. Hann, et al.
Expert Opinion on Drug Discovery (2017) Vol. 12, Iss. 9, pp. 925-940
Open Access | Times Cited: 154
Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint
Katarzyna Magiera‐Mularz, Łukasz Skalniak, Krzysztof M. Zak, et al.
Angewandte Chemie International Edition (2017) Vol. 56, Iss. 44, pp. 13732-13735
Open Access | Times Cited: 149
Small Molecules Drive Big Improvements in Immuno-Oncology Therapies
Bayard R. Huck, Lisa Kötzner, Klaus Urbahns
Angewandte Chemie International Edition (2017) Vol. 57, Iss. 16, pp. 4412-4428
Open Access | Times Cited: 133
Current status of immunotherapy in metastatic colorectal cancer
Paweł Wróbel, Shahid Ahmed
International Journal of Colorectal Disease (2018) Vol. 34, Iss. 1, pp. 13-25
Closed Access | Times Cited: 133
Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles
Katarzyna Guzik, Marcin D. Tomala, Damian Muszak, et al.
Molecules (2019) Vol. 24, Iss. 11, pp. 2071-2071
Open Access | Times Cited: 131
Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
Sara Verdura, Elisabet Cuyàs, Èric Cortada, et al.
Aging (2020) Vol. 12, Iss. 1, pp. 8-34
Open Access | Times Cited: 128
Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules
Xin Lin, Xiang Lu, Guoshun Luo, et al.
European Journal of Medicinal Chemistry (2019) Vol. 186, pp. 111876-111876
Closed Access | Times Cited: 127
Immune Checkpoint PD‐1/PD‐L1: Is There Life Beyond Antibodies?
Markella Konstantinidou, Tryfon Zarganes‐Tzitzikas, Katarzyna Magiera‐Mularz, et al.
Angewandte Chemie International Edition (2017) Vol. 57, Iss. 18, pp. 4840-4848
Open Access | Times Cited: 125
Page 1 - Next Page

Scroll to top